A subsequent phase I/II clinical trial was carried out to evaluate cord blood-derived memory-like NK cells pre-complexed with AFM13 followed by AFM13 infusions for the treatment of relapsed or refractory CD30+ lymphoma [181]. Here, TNFRSF8 is linked to lymphoma.